LIBRA trial: A Randomized trial to assess clinical utility of LINE-electronic patient reported outcomes for the management of adverse events in breast cancer patients treated with abemaciclib

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Abemaciclib (Primary) ; Aromatase inhibitors; Fulvestrant; Leuprorelin
Indications Advanced breast cancer; Male breast cancer
Focus Adverse reactions
Acronyms LIBRA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com